NADH-ubiquinone oxidoreductase 20 kDa subunit Antibody

What is the NADH-ubiquinone oxidoreductase 20 kDa subunit (NDUFS7) and what is its function?

NDUFS7 (also known as PSST, CI-20kD, or Complex I-20kD) is a core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I). This protein is essential for the catalytic activity of Complex I, which functions to catalyze electron transfer from NADH through the respiratory chain using ubiquinone as an electron acceptor . The NDUFS7 subunit specifically plays a key role in coupling electron transfer from iron-sulfur cluster N2 to quinone, making it critical for the terminal electron transfer step in this process . This ~21 kDa protein is highly expressed in tissues with elevated energy requirements such as the heart, brain, and skeletal muscle . Along with other subunits like NDUFS1 and NDUFS2, NDUFS7 ensures proper assembly and function of Complex I, a critical component of cellular energy production.

Why are NDUFS7 antibodies important for mitochondrial research?

NDUFS7 antibodies serve as valuable tools for investigating mitochondrial function, particularly in relation to Complex I assembly, activity, and involvement in pathological conditions. These antibodies allow researchers to detect, quantify, and localize the NDUFS7 protein in various experimental contexts. Since Complex I dysfunction is implicated in numerous mitochondrial disorders and neurodegenerative diseases, NDUFS7 antibodies provide a means to examine alterations in this critical subunit. The antibodies enable Western blotting to assess protein expression levels, immunohistochemistry to visualize tissue distribution patterns, and immunoprecipitation to study protein-protein interactions within the respiratory chain . Additionally, NDUFS7 antibodies can help identify structural and functional changes in Complex I during cellular stress, aging, or disease states, contributing to our understanding of mitochondrial biology and potential therapeutic interventions.

What are the recommended applications for NDUFS7 antibodies in basic research?

NDUFS7 antibodies are versatile tools with several recommended applications in basic research:

• Western Blotting (WB): For quantitative analysis of NDUFS7 expression levels in tissue or cell lysates, allowing comparison between different experimental conditions or disease states .

• Immunohistochemistry on Paraffin Sections (IHC-P): For examining the tissue distribution and subcellular localization of NDUFS7, particularly in tissues with high energy demands like brain, heart, and skeletal muscle .

• Complex I Assembly Studies: For investigating the incorporation of NDUFS7 into the respiratory chain complex during mitochondrial biogenesis or in response to cellular stressors.

• Mitochondrial Dysfunction Analysis: For assessing potential alterations in NDUFS7 levels or localization in models of mitochondrial disease, neurodegenerative disorders, or aging.

• Co-immunoprecipitation: For exploring interactions between NDUFS7 and other Complex I subunits or regulatory proteins that may influence respiratory chain function.

Each application requires specific optimization of antibody concentrations, incubation conditions, and detection methods to ensure specific and sensitive detection of the NDUFS7 protein.

How does NDUFS7/PSST subunit contribute to the electron transfer mechanism in Complex I?

The NDUFS7/PSST subunit plays a critical role in the terminal electron transfer step within Complex I by functionally coupling iron-sulfur cluster N2 to ubiquinone . This represents one of the most crucial and least understood steps in the respiratory chain. Research has established that PSST contains a conserved inhibitor-binding site that is exceptionally sensitive to high-potency inhibitors such as rotenone, piericidin A, bullatacin, and pyridaben .

The electron transfer mechanism involves a sequential process where NADH donates electrons to FMN (the primary electron acceptor), followed by transfer through a series of iron-sulfur clusters, with N2 being the terminal iron-sulfur cluster. NDUFS7/PSST facilitates the final electron transfer step from N2 to ubiquinone. Photoaffinity labeling studies using [³H]TDP (trifluoromethyl)diazirinyl[³H]pyridaben) have demonstrated specific and saturable binding to the PSST subunit, confirming its direct involvement in this electron transfer process .

The redox potential difference between N2 and flavin (at least 200 mV) contributes to the thermodynamics of this intramolecular electron transfer . Importantly, this electron transfer process is coupled to proton translocation, with a stoichiometry of 4 protons per pair of electrons transferred, which is essential for establishing the proton motive force required for ATP synthesis .

What experimental approaches can be used to investigate the interaction between NDUFS7 and inhibitors of Complex I?

Several sophisticated experimental approaches can be employed to investigate interactions between NDUFS7 and Complex I inhibitors:

• Photoaffinity Labeling: Using photoreactive inhibitor analogs (like [³H]TDP) to covalently label the binding site on NDUFS7. This technique has proven highly effective in identifying the PSST subunit as containing a high-affinity binding site for Complex I inhibitors . The approach involves:

  • Incubation with radiolabeled photoaffinity probe

  • UV irradiation to activate the probe

  • Isolation and identification of labeled proteins

• Competitive Binding Assays: These assess whether different inhibitors compete for the same binding site on NDUFS7, providing insights into structure-activity relationships:

  • Pre-incubation with unlabeled inhibitor

  • Addition of labeled probe (e.g., [³H]TDP)

  • Quantification of reduced labeling indicates competition for the same site

• Enzyme Kinetics Analysis: Investigating how inhibitors affect Complex I activity by examining:

• Site-Directed Mutagenesis: Modifying specific residues in NDUFS7 to determine their involvement in inhibitor binding and subsequent effects on enzyme activity.

• Structural Studies: Using cryo-electron microscopy or X-ray crystallography to visualize the NDUFS7-inhibitor complex, though this remains challenging due to the size and complexity of Complex I.

These approaches, often used in combination, provide comprehensive insights into how various inhibitors interact with NDUFS7 and affect Complex I function.

What is the significance of the NDUFS7 subunit in the context of mitochondrial diseases and how can antibodies help investigate disease mechanisms?

The NDUFS7 subunit holds substantial significance in mitochondrial pathology due to its essential role in Complex I function. As a core catalytic subunit involved in electron transfer, alterations in NDUFS7 can directly impact energy production and mitochondrial homeostasis. Mutations or dysfunction in this subunit may contribute to mitochondrial diseases characterized by Complex I deficiency, which often manifest with neurological, cardiac, and muscular symptoms.

Antibodies against NDUFS7 serve as critical tools for investigating disease mechanisms through multiple approaches:

• Protein Expression Analysis: NDUFS7 antibodies enable quantification of protein levels in patient samples compared to healthy controls, revealing whether reduced Complex I activity correlates with altered NDUFS7 expression .

• Post-translational Modification Detection: Custom modified antibodies can detect potential disease-associated post-translational modifications of NDUFS7 that may affect its function or stability.

• Complex I Assembly Assessment: By combining NDUFS7 antibodies with antibodies against other Complex I subunits, researchers can evaluate whether pathogenic mutations affect complex assembly through Blue Native PAGE techniques followed by immunoblotting.

• Tissue-Specific Manifestations: Immunohistochemistry with NDUFS7 antibodies allows examination of affected tissues to determine whether specific cell types show greater vulnerability to NDUFS7 dysfunction .

• Therapeutic Intervention Evaluation: NDUFS7 antibodies can monitor changes in protein expression or localization following potential therapeutic interventions aimed at improving mitochondrial function.

The NDUFS7 protein has particular relevance in neurodegenerative conditions like Parkinson's disease, where Complex I inhibition by toxins such as 1-methyl-4-phenylpyridinium ion (MPP⁺) plays a causative role . Antibody-based studies help elucidate whether NDUFS7 represents a specific target in these pathological processes.

What are the critical parameters for optimizing Western blot protocols with NDUFS7 antibodies?

Optimizing Western blot protocols for NDUFS7 detection requires careful consideration of several critical parameters:

• Sample Preparation:

  • Use freshly prepared mitochondrial fractions or total cell lysates from tissues with high energy demands (heart, brain, skeletal muscle)

  • Include protease inhibitors to prevent degradation of the 21 kDa NDUFS7 protein

  • Maintain cold temperatures throughout extraction to preserve protein integrity

• Protein Separation:

  • Use 12-15% polyacrylamide gels for optimal resolution of the ~21 kDa NDUFS7 protein

  • Load appropriate controls, including positive controls from tissues known to express high levels of NDUFS7

  • Consider using gradient gels when simultaneously detecting other Complex I subunits

• Transfer Conditions:

  • Employ wet transfer methods for more consistent results with mitochondrial proteins

  • Use methanol-containing transfer buffer to enhance binding of hydrophobic mitochondrial proteins to membranes

  • Optimize transfer time and voltage to prevent protein loss while ensuring complete transfer

• Antibody Incubation:

  • Start with recommended dilutions for the specific NDUFS7 antibody (e.g., 1:1000 for Abcam ab105025)

  • Perform dilution series to determine optimal concentration for your specific samples

  • Include prolonged incubation times (overnight at 4°C) for maximum sensitivity

• Detection Method:

  • Use enhanced chemiluminescence for standard applications

  • Consider fluorescent secondary antibodies for multiplexing with other respiratory chain components

  • Include appropriate loading controls specific for mitochondrial proteins (e.g., VDAC, COX IV)

• Validation Strategies:

  • Include relevant positive and negative controls

  • Consider using NDUFS7 knockdown or knockout samples as specificity controls

  • Verify band identity using recombinant NDUFS7 protein as reference

Following these optimization steps will help ensure specific and sensitive detection of NDUFS7 protein in your experimental system.

How can researchers differentiate between effects on NDUFS7 versus other Complex I subunits when studying electron transfer mechanisms?

Differentiating effects specific to NDUFS7 from those involving other Complex I subunits requires sophisticated experimental approaches:

• Subunit-Specific Inhibitor Studies:

  • Utilize inhibitors with known binding preferences for NDUFS7/PSST, such as pyridaben derivatives

  • Compare effects with inhibitors targeting different Complex I subunits

  • Analyze inhibition patterns using the following comparative approach:

These approaches, particularly when combined, allow researchers to distinguish NDUFS7-specific effects from those involving other Complex I components, providing clearer insights into the precise role of this subunit in electron transfer mechanisms.

What technical challenges may arise when using NDUFS7 antibodies for immunohistochemistry and how can they be addressed?

Immunohistochemical detection of NDUFS7 presents several technical challenges that researchers should anticipate and address:

• Fixation and Epitope Masking:

  • Challenge: Formalin fixation can mask NDUFS7 epitopes, particularly those located within the protein's core.

  • Solution: Implement optimized antigen retrieval protocols, testing both heat-mediated (citrate or EDTA buffers at varying pH) and enzymatic methods to determine which best exposes NDUFS7 epitopes without compromising tissue morphology.

• Mitochondrial Density Variations:

  • Challenge: NDUFS7 signal intensity naturally varies between tissues due to differences in mitochondrial content.

  • Solution: Co-stain with mitochondrial mass markers (e.g., TOMM20, VDAC) to normalize NDUFS7 signals to mitochondrial content rather than total tissue area, particularly when comparing different tissue types or disease states.

• Background and Non-specific Binding:

  • Challenge: Polyclonal antibodies like ab105025 may exhibit some non-specific binding .

  • Solution: Implement rigorous blocking protocols with both protein blockers (BSA or serum) and biotin/avidin blocking systems if using biotin-based detection methods. Consider using monovalent Fab fragments to block endogenous immunoglobulins in human tissues.

• Sensitivity in Low-Expression Regions:

  • Challenge: Detecting NDUFS7 in tissues with lower expression levels.

  • Solution: Employ signal amplification systems such as tyramide signal amplification (TSA) or polymer-based detection systems to enhance sensitivity while maintaining specificity.

• Autofluorescence Interference:

  • Challenge: Mitochondria-rich tissues often exhibit significant autofluorescence, particularly after formalin fixation.

  • Solution: Use Sudan Black B treatment to quench autofluorescence, consider spectral unmixing microscopy techniques, or select fluorophores with emission spectra distinct from tissue autofluorescence.

• Antibody Validation Concerns:

  • Challenge: Confirming antibody specificity in tissue sections.

  • Solution: Include appropriate controls, including peptide competition assays with the immunizing peptide (aa 50-100 of human NDUFS7) , tissues from relevant knockout models if available, and comparison with alternative antibodies targeting different epitopes of NDUFS7.

• Subcellular Resolution Limitations:

  • Challenge: Standard IHC may not provide sufficient resolution to distinguish individual mitochondria.

  • Solution: Complement IHC with super-resolution microscopy techniques when subcellular localization is critical, potentially combining NDUFS7 antibodies with markers for mitochondrial subcompartments.

Implementing these technical solutions significantly improves the reliability and interpretability of NDUFS7 immunohistochemistry results in research applications.

How can NDUFS7 antibodies be used to study the relationship between Complex I dysfunction and neurodegenerative diseases?

NDUFS7 antibodies provide powerful tools for investigating the mechanistic links between Complex I dysfunction and neurodegenerative pathologies through multiple research approaches:

• Post-mortem Tissue Analysis:

  • Apply NDUFS7 antibodies for immunohistochemistry on brain sections from Parkinson's disease, Alzheimer's disease, and other neurodegenerative disorder patients

  • Quantify changes in NDUFS7 expression patterns across different brain regions and compare with age-matched controls

  • Correlate NDUFS7 alterations with disease severity, protein aggregation markers, and neuronal loss

• Neurotoxin Models:

  • Analyze NDUFS7 status in cellular and animal models treated with Complex I inhibitors implicated in Parkinson's disease (e.g., MPP⁺, rotenone)

  • Assess whether NDUFS7 is directly modified by these toxins using immunoprecipitation followed by mass spectrometry

  • Monitor temporal changes in NDUFS7 localization and levels relative to onset of neurodegeneration

• Patient-Derived Models:

  • Use NDUFS7 antibodies to characterize Complex I status in patient-derived fibroblasts, iPSC-derived neurons, or organoids

  • Compare NDUFS7 incorporation into Complex I between patient and control samples using blue native PAGE followed by immunoblotting

  • Examine responses to energetic stress and correlation with mitochondrial dysfunction phenotypes

• Therapeutic Intervention Assessment:

  • Apply NDUFS7 antibodies to evaluate whether neuroprotective compounds restore normal Complex I assembly and NDUFS7 incorporation

  • Monitor changes in NDUFS7-ubiquinone interactions using proximity ligation assays before and after treatment

  • Determine if therapeutic candidates prevent inhibitor binding to the PSST/NDUFS7 subunit

• Genetic Model Characterization:

  • Validate NDUFS7 knockdown or knockout models using specific antibodies

  • Assess compensatory changes in other Complex I subunits when NDUFS7 is compromised

  • Investigate whether genetic rescue approaches restore normal NDUFS7 levels and functionality

These applications of NDUFS7 antibodies in neurodegenerative disease research specifically address the critical role of this subunit in the terminal electron transfer step of Complex I, which appears particularly vulnerable in conditions like Parkinson's disease .

What methodological approaches can be used to study the redox-dependent binding affinities of nucleotides to Complex I using NDUFS7 antibodies?

Investigating redox-dependent nucleotide binding to Complex I requires sophisticated methodological approaches that can incorporate NDUFS7 antibodies as key analytical tools:

• Comparative Pull-down Assays:

  • Prepare mitochondrial membranes or isolated Complex I in defined redox states (oxidized vs. reduced)

  • Immobilize nucleotides (NADH, NAD⁺, NADH-OH, ADP-ribose) on affinity matrices

  • Use NDUFS7 antibodies to detect and quantify bound Complex I in different redox states

  • Compare binding patterns with the established affinity values :

• Cross-linking Coupled with Immunoprecipitation:

  • Treat Complex I in different redox states with photoactivatable nucleotide analogs

  • Cross-link nucleotides to their binding sites using UV irradiation

  • Immunoprecipitate with NDUFS7 antibodies to determine if NDUFS7 is directly involved in nucleotide binding

  • Analyze by mass spectrometry to identify binding sites and redox-dependent modifications

• Conformational Change Assessment:

  • Apply limited proteolysis to Complex I in different redox states with/without bound nucleotides

  • Use NDUFS7 antibodies in Western blots to detect changes in proteolytic pattern

  • Map conformational changes that correlate with altered nucleotide binding affinities

  • This approach can identify whether NDUFS7 undergoes structural changes during redox transitions that influence nucleotide binding

• Microscale Thermophoresis with Immunocapture:

  • Isolate Complex I using NDUFS7 antibodies coupled to solid support

  • Label purified complex with fluorescent dyes that don't interfere with nucleotide binding

  • Measure thermophoretic mobility shifts upon titration with different nucleotides

  • Compare binding parameters between oxidized and reduced states of the enzyme

• Surface Plasmon Resonance Analysis:

  • Immobilize NDUFS7 antibodies on sensor chips

  • Capture Complex I in controlled redox states

  • Measure binding kinetics of various nucleotides in real-time

  • Derive association and dissociation constants under different redox conditions

These methodological approaches provide complementary data on how the redox state of Complex I influences nucleotide binding, with particular focus on whether NDUFS7 plays a direct or indirect role in these interactions, building upon the established differences in binding affinities documented in previous research .

How can researchers use NDUFS7 antibodies to investigate the assembly and stability of Complex I under different cellular stress conditions?

NDUFS7 antibodies provide valuable tools for examining Complex I assembly and stability under various cellular stressors, enabling researchers to track this critical subunit throughout the complex's lifecycle:

• Blue Native PAGE Combined with Western Blotting:

  • Subject cells to stress conditions (oxidative stress, hypoxia, nutrient deprivation)

  • Isolate mitochondria and solubilize with gentle detergents to preserve Complex I integrity

  • Separate native complexes using blue native PAGE

  • Perform Western blotting using NDUFS7 antibodies to detect:

    • Fully assembled Complex I (~980 kDa)

    • Assembly intermediates containing NDUFS7

    • Degradation products during stress-induced disassembly

  • Compare the distribution patterns across different stress conditions and recovery periods

• Pulse-Chase Experiments:

  • Metabolically label newly synthesized proteins with amino acid isotopes

  • Chase through stress exposure periods

  • Immunoprecipitate NDUFS7 at different timepoints

  • Analyze incorporation into Complex I and turnover rates

  • This approach reveals whether NDUFS7 stability is particularly affected by specific stressors

• Co-immunoprecipitation Studies:

  • Use NDUFS7 antibodies to immunoprecipitate the protein and its interacting partners

  • Compare interaction profiles between normal and stress conditions

  • Identify stress-specific interactions with chaperones, assembly factors, or degradation machinery

  • Quantify changes in associations with other Complex I subunits, particularly those known to interact directly with NDUFS7:

    • NDUFS1 (75 kDa subunit)

    • NDUFS2 (49 kDa subunit)

    • ND1 (mitochondrially encoded subunit)

• Fluorescence Recovery After Photobleaching (FRAP):

  • Generate cell lines expressing fluorescently tagged NDUFS7

  • Subject to various stressors

  • Perform FRAP analysis to measure:

    • Mobility of NDUFS7-containing complexes

    • Rate of incorporation into mitochondrial membranes

    • Changes in diffusion coefficients under stress

• Protease Susceptibility Assays:

  • Isolate mitochondria from stressed and control cells

  • Perform controlled protease digestions with increasing concentrations

  • Use NDUFS7 antibodies to monitor degradation patterns by Western blotting

  • Increased susceptibility indicates structural destabilization of Complex I

• Proximity Ligation Assays:

  • Apply NDUFS7 antibodies together with antibodies against other Complex I subunits

  • Quantify proximity signals in situ under different stress conditions

  • Map which interactions are most sensitive to specific stressors

  • Correlate changes with functional impairments in electron transfer

These methodologies collectively provide comprehensive insights into how cellular stressors affect the assembly, stability, and turnover of Complex I, with particular focus on the NDUFS7 subunit that plays a critical role in electron transfer to ubiquinone .

What are the current limitations in research using NDUFS7 antibodies and what future developments might address these challenges?

Current research with NDUFS7 antibodies faces several important limitations, alongside promising developments that may overcome these challenges:

Current Limitations:

• Antibody Specificity Concerns: Most commercially available NDUFS7 antibodies are polyclonal (like ab105025) , which can introduce batch-to-batch variability and potential cross-reactivity with other mitochondrial proteins of similar molecular weight.

• Limited Species Cross-Reactivity: Many available antibodies are optimized for human samples, with variable efficacy in model organisms, restricting comparative studies across species despite the conserved nature of this protein between mitochondria and bacteria .

• Conformational Epitope Recognition: Current antibodies may not recognize NDUFS7 equally well in all its conformational states, particularly during the redox-dependent changes that occur during catalysis , potentially biasing detection toward certain functional states.

• Resolution Limitations: Standard immunological techniques lack sufficient resolution to visualize the precise location of NDUFS7 within the Complex I structure during different functional states.

• Quantification Challenges: Accurately quantifying NDUFS7 levels relative to other Complex I subunits remains difficult due to differences in antibody affinities and extraction efficiencies.

Future Developments:

• Monoclonal Antibody Generation: Development of high-specificity monoclonal antibodies against defined epitopes of NDUFS7, potentially including conformation-specific antibodies that recognize particular functional states.

• Super-Resolution Compatible Probes: Creation of antibody-based probes optimized for super-resolution microscopy techniques (STORM, PALM, STED) to visualize NDUFS7 localization with nanometer precision within mitochondria.

• Intrabodies and Nanobodies: Engineering of cell-permeable intrabodies or nanobodies against NDUFS7 that can track the protein in living cells without fixation artifacts, potentially paired with fluorescent reporters for real-time imaging.

• Proximity-Labeling Antibody Conjugates: Development of NDUFS7 antibodies conjugated to proximity-labeling enzymes (BioID, APEX) to map the dynamic protein interaction landscape during different cellular states.

• Cross-Species Optimized Antibodies: Creation of antibodies specifically designed to recognize conserved epitopes across species, enabling comparative studies between mammalian models and bacterial systems with homologous proteins like NQO6 .

These future developments would significantly advance our ability to study NDUFS7's role in Complex I function, electron transfer mechanisms, and involvement in mitochondrial pathologies, addressing the technical limitations that currently constrain research in this field.